Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 9 PAGES: 173

More Info
									Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1749IDB
                                                                                           Publication Date: February 2012




Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012                                      GMDHC1749IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 12
Introduction....................................................................................................................................................................................... 13
    Global Markets Direct Report Coverage ...................................................................................................................................... 13
Atopic Dermatitis (Eczema) Overview .............................................................................................................................................. 14
Therapeutics Development............................................................................................................................................................... 15
    An Overview of Pipeline Products for Atopic Dermatitis (Eczema) .............................................................................................. 15
Atopic Dermatitis (Eczema) Therapeutics under Development by Companies ................................................................................ 17
Atopic Dermatitis (Eczema) Therapeutics under Investigation by Universities/Institutes.................................................................. 22
Late Stage Products ......................................................................................................................................................................... 24
    Comparative Analysis .................................................................................................................................................................. 24
Mid Clinical Stage Products.............................................................................................................................................................. 25
    Comparative Analysis .................................................................................................................................................................. 25
Early Clinical Stage Products ........................................................................................................................................................... 26
    Comparative Analysis .................................................................................................................................................................. 26
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 27
    Comparative Analysis .................................................................................................................................................................. 27
Atopic Dermatitis (Eczema) Therapeutics – Products under Development by Companies .............................................................. 28
Atopic Dermatitis (Eczema) Therapeutics – Products under Investigation by Universities/Institutes................................................ 30
Companies Involved in Atopic Dermatitis (Eczema) Therapeutics Development ............................................................................. 31
    Bayer HealthCare AG .................................................................................................................................................................. 31
    Amgen Inc. .................................................................................................................................................................................. 32
    GlaxoSmithKline plc .................................................................................................................................................................... 33
    Daiichi Sankyo Company, Ltd...................................................................................................................................................... 34
    Novartis AG ................................................................................................................................................................................. 35
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 36
    Eisai Co., Ltd. .............................................................................................................................................................................. 37
    Galderma S.A. ............................................................................................................................................................................. 38
    LEO Pharma A/S ......................................................................................................................................................................... 39
    Almirall, S.A. ................................................................................................................................................................................ 40
    NicOx SA ..................................................................................................................................................................................... 41
    Regeneron Pharmaceuticals, Inc................................................................................................................................................. 42
    Hanall Pharmaceutical Co., Ltd. .................................................................................................................................................. 43
    AnGes MG, Inc. ........................................................................................................................................................................... 44
    Biotie Therapies Corp. ................................................................................................................................................................. 45
    Provectus Pharmaceuticals, Inc. ................................................................................................................................................. 46
    Proximagen Neuroscience plc. .................................................................................................................................................... 47
    R-Tech Ueno, Ltd. ....................................................................................................................................................................... 48
    Fougera ....................................................................................................................................................................................... 49
    Paloma Pharmaceuticals, Inc. ..................................................................................................................................................... 50
    Asubio Pharmaceuticals, Inc. ...................................................................................................................................................... 51



Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012                                                                                      GMDHC1749IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012




    Palau Pharma S.A ....................................................................................................................................................................... 52
    Respiratorius AB.......................................................................................................................................................................... 53
    MIKA Pharma GmbH ................................................................................................................................................................... 54
    PLANTON GmbH ........................................................................................................................................................................ 55
    CREABILIS Therapeutics S.r.l. .................................................................................................................................................... 56
    Anacor Pharmaceuticals, Inc. ...................................................................................................................................................... 57
    JADO Technologies GmbH. ........................................................................................................................................................ 58
    IMMD Inc. .................................................................................................................................................................................... 59
    Circassia Holdings Ltd. ................................................................................................................................................................ 60
    Hawthorn Pharmaceuticals, Inc. .................................................................................................................................................. 61
    Melior Discovery, Inc. .................................................................................................................................................................. 62
    Welichem Biotech Inc. ................................................................................................................................................................. 63
    Cutanea Life Sciences................................................................................................................................................................. 64
    Action Pharma A/S ...................................................................................................................................................................... 65
    SWITCH Biotech LLC .................................................................................................................................................................. 66
    Aerovance, Inc............................................................................................................................................................................. 67
    Maruho Co.,Ltd. ........................................................................................................................................................................... 68
    Pharis Biotec GmbH .................................................................................................................................................................... 69
    Interprotein Corporation ............................................................................................................................................................... 70
    Immune Technologies and Medicine .......................................................................................................................................... 71
    Mantecorp Industria Quimica e Farmaceutica Ltda ..................................................................................................................... 72
    EMS S.A. ..................................................................................................................................................................................... 73
Atopic Dermatitis (Eczema) – Therapeutics Assessment ................................................................................................................. 74
    Assessment by Monotherapy Products ....................................................................................................................................... 74
    Assessment by Combination Products ........................................................................................................................................ 75
    Assessment by Route of Administration ...................................................................................................................................... 76
    Assessment by Molecule Type .................................................................................................................................................... 78
Drug Profiles..................................................................................................................................................................................... 80
    GW870086 - Drug Profile ............................................................................................................................................................ 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    MK52 - Drug Profile ..................................................................................................................................................................... 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    MK51 - Drug Profile ..................................................................................................................................................................... 82
        Product Description................................................................................................................................................................. 82
        Mechanism of Action ............................................................................................................................................................... 82
        R&D Progress ......................................................................................................................................................................... 82
    MK50 - Drug Profile ..................................................................................................................................................................... 83
        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83


Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012                                                                                      GMDHC1749IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Atopic Dermatitis (Eczema) – Pipeline Review, H1 2012




    SUN13834 - Drug Profile ............................................................................................................................................................. 84
        Product Description................................................................................................................................................................. 84
        Mechanism of Action ............................................................................................................................................................... 84
        R&D Progress ......................................................................................................................................................................... 84
    NCX 1047 - Drug Profile .............................................................................................................................................................. 85
        Product Description................................................................................................................................................................. 85
        Mechanism of Action ............................................................................................................................................................... 85
        R&D Progress ......................................................................................................................................................................... 85
    DD-1 - Drug Profile ...................................................................................................................................................................... 86
        Product Description................................................................................................................................................................. 86
        Mechanism of Action ............................................................................................................................................................... 86
        R&D Progress ......................................................................................................................................................................... 86
    AMG 157 - Drug Profile ............................................................................................................................................................... 87
        Product Description................................................................................................................................................................. 87
        Mechanism of Action ............................................................................................................................................................... 87
        R&D Progress ......................................................................................................................................................................... 87
    CT327 - Drug Profile.................................................................................................................................................................... 88
        Product Description................................................................................................................................................................. 88
        Mechanism of Action ............................................................................................................................................................... 88
        R&D Progress ......................................................................................................................................................................... 88
    CLS001 - Drug Profile ................................................................................................................................................................. 90
        Product Description................................................................................................................................................................. 90
        Mechanism of Action ............................................................................................................................................................... 90
        R&D Progress ......................................................................................................................................................................... 90
    PH-10 - Drug Profile .................................................................................................................................................................... 92
        Product Description................................................................................................................................................................. 92
        Mechanism of Action ............................................................................................................................................................... 92
        R&D Progress ......................................................................................................................................................................... 92
    DPK-060 - Drug Profile ................................................................................................................................................................ 94
        Product Description................................................................................................................................................................. 94
        Mechanism of Action ............................................................................................................................................................... 94
    
								
To top